Asuragen Releases Updated AmplideX® PCR/CE Reporter Software
AUSTIN, Texas--(BUSINESS WIRE)--Apr 2, 2019--Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy-to-use products for complex testing in genetics and oncology, today announced a substantial update to its AmplideX Reporter software for the automated downstream data analysis of assays in the AmplideX product portfolio. The update incorporates a more efficient and robust architecture that allows assay-specific analysis modules to be added as new AmplideX products become available.
The AmplideX Reporter is a fully automated software solution that streamlines the upload, analysis, and interpretation of data with minimal actions required of the user. It allows for the direct import of .fsa files from supported capillary electrophoresis systems and the generation of sample results in minutes without the need for third party electropherogram analysis tools. Unique features of the software include peak autoselection, minor allele sensitivity customization, integration of multiple QC checks to confirm sample and run integrity, and automated genotyping of every sample. Finally, the software generates results reports in LIMS-friendly formats to ease the upload and management of the information generated. The AmplideX Reporter is supported on Windows 7 and 10 operating systems, as well as Windows Server 2012.
“AmplideX technology provides an innovative and elegant approach to detecting and quantifying these challenging targets. This software adds a robust, easy-to-use data analysis pipeline, making results reporting scalable while reducing opportunity for error,” said Matthew McManus, MD, PhD, president and CEO of Asuragen. “AmplideX Reporter software is a key differentiator for our products, providing our customers with a push-button software solution to generate results simply, accurately, and efficiently.”
The updated AmplideX Reporter with the AmplideX PCR/CE FMR1*† assay analysis module will be unveiled at the upcoming ACMG Annual Clinical Genetics Meeting in Seattle on April 2-6. The company will be showcasing the new software in booth #828, where the company will also be highlighting the recent launch of its AmplideX PCR/CE SMN1/2 Kit *.
* For research use only. Not for use in diagnostic procedures.
† CE-IVD. For US export only.
Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190402005357/en/
CONTACT: Lynne Hohlfeld
SVP, Corporate Development & CFO
2150 Woodward St., Suite 100
Austin, TX 78744
KEYWORD: UNITED STATES NORTH AMERICA TEXAS WASHINGTON
INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE NANOTECHNOLOGY HEALTH BIOTECHNOLOGY GENETICS MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE MANAGED CARE
SOURCE: Asuragen, Inc.
Copyright Business Wire 2019.
PUB: 04/02/2019 08:00 AM/DISC: 04/02/2019 08:03 AM